MAB-22 clinical trials

A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis

This study compares a new medicine called MAB-22 with an existing one, Prolia, for postmenopausal women with osteoporosis. It checks how well they build bone, how the body handles them, and if they are safe. It's to confirm if MAB-22 is a good alternative.